Fanconi anemia genes in lung adenocarcinoma- a pathway-wide study on cancer susceptibility

Table 3 Lung adenocarcinoma risk associated with the number of high-risk genotypes of FANCD2 and FANCI in male and female lung adenocarcinoma patients-Joint effect of component genes in the FA UB complex

Genotype of		No. cases (%)	No. controls (%)	aOR (95 % CI)^a	P for trend
FANCD2 ^b	FANCI ^b
Male lung adenocarcinoma patients
AA	CC	82(27.1)	94(33.6)	1.00(ref.)	0.03
AA	CC, CT	104(34.3)	94(33.6)	1.27(0.94–1.93)
AG,GG	CC	50(16.5)	44(15.7)	1.27(0.94–1.93)
AG,GG	CC,CT	67(22.1)	48(17.1)	1.83(1.08–3.13)
Female lung adenocarcinoma patients
AA	CC	42(14.1)	63(18.9)	1.00(ref.)	0.02
AA	CC,CT	65(21.9)	57(17.1)	1.52(0.95–2.42)
AG,GG	CC	87(29.3)	114(34.1)	1.52(0.95–2.42)
AG,GG	CC,CT	103(34.7)	100(29.9)	1.81(1.10–2.99)

^aaOR, adjusted odds ratio; 95 %CI, 95 % confidence interval. These were estimated in a multivariate logistic regression model, containing age, years of schooling of study participants, and the smoking-related risk factors (i.e., cigarette smoking and passive smoking) identified in Table 2
^bThe SNPs used in the analysis were rs6792811 (FANCD2) and rs9806604(FANCI) in males and rs6792811(FANCD2) and rs9920768(FANCI) in females

ISSN: 1423-0127